ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 77 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,587,495 | -22.0% | 3,568,181 | 0.0% | 14.33% | +33.4% |
| Q2 2023 | $27,689,085 | +36.1% | 3,568,181 | 0.0% | 10.75% | +46.1% |
| Q1 2023 | $20,338,632 | -3.2% | 3,568,181 | 0.0% | 7.35% | +5.1% |
| Q4 2022 | $21,016,586 | +84.1% | 3,568,181 | 0.0% | 7.00% | +176.9% |
| Q3 2022 | $11,418,000 | -28.6% | 3,568,181 | 0.0% | 2.53% | -25.7% |
| Q2 2022 | $15,985,000 | -16.1% | 3,568,181 | 0.0% | 3.40% | -3.7% |
| Q1 2022 | $19,054,000 | -63.7% | 3,568,181 | 0.0% | 3.53% | -50.5% |
| Q4 2021 | $52,452,000 | -47.4% | 3,568,181 | -25.2% | 7.13% | -37.1% |
| Q3 2021 | $99,703,000 | +18.2% | 4,768,181 | 0.0% | 11.34% | -5.0% |
| Q2 2021 | $84,349,000 | -27.8% | 4,768,181 | 0.0% | 11.94% | +6.7% |
| Q1 2021 | $116,820,000 | -27.6% | 4,768,181 | 0.0% | 11.19% | -23.5% |
| Q4 2020 | $161,403,000 | – | 4,768,181 | – | 14.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |